Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

• Status: Not yet recruiting
• Trial end date: 2023-03-21
• Target enrollment: 0
• Participant gender: Female

Summary

Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. Alterations in the peri-implantation environment are considered to impair perinatal outcomes in intracytoplasmic sperm injection (ICSI) therapy. GnRH-a is a new and promising modality for LPS. Regimens for using GnRH-a in LPS, including single mid-luteal bolus or the addition of a GnRH-a to progesterone supplementation, have been recently suggested. The aim of this study is to evaluate the impact of addition of mid-luteal single-dose or multiple-dose GnRH agonist to the routine luteal phase support in patients undergoing ICSI cycles using GnRH antagonist protocol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Hormones; Progesterone; Triptorelin Pamoate

Criteria

Inclusion Criteria:

1. Patient age ≤ 38 years.

2. BMI ≤ 30.

3. Basal follicle stimulating hormone (FSH) level ≤ 10 IU/L.

4. Anti-Müllerian hormone (AMH): ≤ 5 ng/ml.

Exclusion Criteria:

1. Endometriosis.

2. Polycystic ovarian syndrome (PCOS).

3. Uterine pathology or anomaly.

4. Evidence of hydrosalpinx by hysterosalpingography or ultrasound.

5. Comorbidities: Diabetes mellitus, hypertension, immune diseases.